Short Interest in RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) Increases By 107.0%

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 166,600 shares, an increase of 107.0% from the January 31st total of 80,500 shares. Based on an average trading volume of 1,284,500 shares, the days-to-cover ratio is currently 0.1 days.

RespireRx Pharmaceuticals Price Performance

OTCMKTS:RSPI traded up $0.00 during mid-day trading on Friday, hitting $0.00. 1,000 shares of the stock were exchanged, compared to its average volume of 479,332. RespireRx Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.01.

RespireRx Pharmaceuticals Company Profile

RespireRx Pharmaceuticals Inc engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.